As of May, 8 Ionis Pharmaceuticals, Inc. (IONS) Analysts See $-0.11 EPS

April 16, 2018 - By Mary Markley

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Corporate Logo

On May, 8 WallStreet anticipated Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s earnings release, as reported by RTT. EPS of $-0.11 is 466.67 % down from 2017’s $0.03 EPS. -650.00 % negative EPS growth is what Wall Street’s sees after $0.02 reported EPS last quarter. The stock decreased 0.34% or $0.15 during the last trading session, reaching $43.47.Ionis Pharmaceuticals, Inc. has volume of 494,080 shares. Since April 17, 2017 IONS has risen 14.82% and is uptrending. IONS outperformed by 3.27% the S&P 500.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics.The company has $5.45 billion market cap. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet.Last it reported negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.